PineocytomaSymptoms, Doctors, Treatments, Advances & More
Pineocytoma Overview
Learn About Pineocytoma
- Pineocytoma
- Pinealocytoma
- Pinealoma
Adult Neurofibromatosis Type 1 (NF1) And Schwannomatosis Clinic
Dr. David Raleigh is a radiation oncologist who specializes in brain tumors. He cares for both adult and pediatric patients. Raleigh's research focuses on understanding the biological processes that cause brain tumors to grow. His goals are to uncover new measures of brain cancer and to identify cells for drugs to target. Raleigh earned a bachelor's degree in molecular and cell biology as well as a bachelor's degree in cognitive science from the University of California, Berkeley. He earned his doctoral degree in molecular pathogenesis – how disease develops at the molecular level – from the University of Chicago, followed by his medical degree from the Pritzker School of Medicine at the University of Chicago. He completed a residency in radiation oncology at UCSF. Raleigh is a member of the American Society of Clinical Oncology, American Society for Radiation Oncology, Pacific Pediatric Neuro-Oncology Consortium, Children's Oncology Group, Society for Neuro-Oncology, International Meningioma Society and North American Skull Base Society. At the UCSF Brain Tumor Center, Raleigh is a principal investigator with the Wolfe Meningioma Program Project. Dr. Raleigh is rated as an Elite provider by MediFind in the treatment of Pineocytoma. His top areas of expertise are Meningioma, Pineocytoma, Brain Tumor, and Gliomatosis Cerebri.
Joham Velasquez-Choque practices in Helsinki, Finland. Velasquez-Choque is rated as an Elite expert by MediFind in the treatment of Pineocytoma. Their top areas of expertise are Pineocytoma, Vein of Galen Aneurysm, Rathke Cleft Cyst, Nerve Decompression, and Extracranial-Intracranial Bypass Surgery.
Hospices Civils De Lyon
Alexandre Vasiljevic practices in Bron, France. Mr. Vasiljevic is rated as an Elite expert by MediFind in the treatment of Pineocytoma. His top areas of expertise are Pineocytoma, Pituitary Tumor, Hypothalamic Tumor, and Brain Tumor.
Summary: This is an open-label phase 1 safety and feasibility study that will employ multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA) derived from a patient's primary brain tumor tissues. Young patients with embryonal central nervous system (CNS) malignancies typically are unable to receive irradiation due ...
Summary: This is a single-site, open-label Phase 1 clinical trial evaluating the feasibility, safety, and preliminary activity of autologous GPC2-targeted chimeric antigen receptor (CAR) T cells administered via intracerebroventricular (ICV) infusion in children and young adults with relapsed or refractory medulloblastoma or other eligible Central Nervous System (CNS) embryonal tumors.
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center
